Irbesartan

This MedLibrary.org supplementary page on Irbesartan is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Irbesartan
Systematic (IUPAC) name
2-butyl-
3-p-(o-1H-tetrazol-5-ylphenyl)benzyl]-
1,3-diazaspiro[4.4]non-1-en-4-one
Identifiers
CAS number 138402-11-6
ATC code C09CA04
PubChem 3749
DrugBank APRD00413
Chemical data
Formula C25H28N6O 
Mol. mass 428.53
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 60–80%
Metabolism Hepatic (CYP2C9)
Half life 11–15 hours
Excretion Renal 20%, faecal 65%
Therapeutic considerations
Licence data

EU, US
Pregnancy cat.

D (Au)
Legal status

S4 (Au), POM (UK), ℞-only (U.S.)
Routes Oral

Irbesartan (INN) (pronounced /ɜrbəˈsɑrtən/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

Contents

Clinical use

Main article: Angiotensin II receptor antagonist

Indications

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2]

Combination with diuretic

Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including Irda, CoIrda, CoAprovel, Karvezide, Avalide and Avapro HCT.

References

  1. ^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes". N Engl J Med 345 (12): 851–60. doi:10.1056/NEJMoa011303. PMID 11565517. 
  2. ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3

See also

v • d • e
Agents acting on the renin-angiotensin system (C09)
ACE inhibitors
Angiotensin II receptor antagonists (AIIRA)
Renin inhibitors

Wikipedia content modification information:

  • This page was last modified on 8 July 2008, at 13:48.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Irbesartan".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.